

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.



Substitute for form 1449A/PTO				Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Application Number	10/625,116		
				Filing Date	July 22, 2003		
				First Name Inventor	Jolidon, et al.		
Sheet	1	of	1	Attorney Docket Number	21229 US		
U.S. PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
	A						
FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ³
		Office ⁴	Number ⁴	Kind Code ⁵ (if known)			
GS	B1		WO 01/34172		Vela Pharmaceuticals Inc.	05/17/2001	
GS	B2		WO 97/33572		Somerset Pharmaceuticals Inc.	09/18/1997	
GS	B3		WO 96/40095		Harris, Richard, Y.	12/19/1996	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ³
GS	C1	Bach et al., Proc. Natl. Acad. Sci. USA 85:4934-4938 (July, 1988)	
	C2	Cesura & Pletscher, Prog. Drug Research 38:171-297 (1992)	
	C3	Fowler et al., J. Neural. Transm. 49:1-20 (1980)	
	C4	M. S. Benedetti et al., Biochem. Pharmacol. 38:555-561 (1989)	
	C5	Saura et al., Neuroscience 70:755-774 (1996)	
	C6	Bentué-Ferrer et al., in CNS Drugs 6:217-236 (1996)	
	C7	Gardner et al., J. Clin. Psychiatry 57(3): 99-104 (1996)	
	C8	Schlaeger & Christensen, Cytotechnology 30: 71-83 (1999)	
	C9	Zhou & Panchuk-Voloshina, Analytical Biochemistry 253: 169-174 (1997)	
GS	C10	Grethe et al., J. Org. Chem. 33: 494-503 (1968)	

Examiner Signature	<i>Amir Shameem</i>	Date Considered	8/30/04
-----------------------	---------------------	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
²Unique citation designation number. ³See attached Kinds of U.S. Patent Documents. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation or abstract is attached.